WHO Pharmaceuticals Newsletter 2004, No. 03
(2004; 12 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentARIPIPRAZOLE, CLOZAPINE, QUETIAPINE AND OTHER ATYPICAL ANTI-PSYCHOTICS - Label to indicate risk of hyperglycaemia and diabetes
View the documentMUROMONAB-CD3 - Serious adverse reactions in paediatric patients
View the documentNU BAO - Presence of animal derivatives and human tissue poses health risks
View the documentOTC DRUGS - New labelling rules to increase safety
View the documentSHITEK TONGKAT ALI PLUS 400MG - Presence of tadalafil
View the documentTOLCAPONE - Marketing reauthorized, but more stringent monitoring recommended
View the documentTRAZODONE - Interactions with CYP3A4 inhibitors/inducers
Open this folder and view contentsSAFETY OF MEDICINES
View the documentFEATURE
 

NU BAO - Presence of animal derivatives and human tissue poses health risks

UK. The patient information leaflet for a traditional Chinese medicine named Nu Bao lists human placenta, deer antler (Corna cervi oantotrichum) and donkey skin (Colla cori astini) as the ingredients present in the capsules of the product. Although the information on the source of these ingredients is limited, the Medicines and Healthcare Products Regulatory Agency (MHRA) advices that all animal and human tissue derivatives carry a potential risk of infectious diseases due to the transmission of infective bacteria and viruses. The MHRA is therefore advising that consumers should not take this product. Current users should stop taking the product and should consult their doctor if they feel unwell. The MHRA has written to suppliers to cease marketing Nu Bao with immediate effect.

Reference:

Herbal Safety News, May 2004. Available from URL: http://medicines.mhra.gov.uk

to previous section to next section
 

Last updated: May 3, 2013